Q4 2014 13F Holders as of 12/31/2014
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
12.2M
-
Shares change
-
+134K
-
Total reported value, excl. options
-
$215M
-
Value change
-
+$2.4M
-
Number of buys
-
20
-
Number of sells
-
-20
-
Price
-
$17.65
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2014
50 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2014.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.2M shares
of 108M outstanding shares and own 11.32% of the company stock.
Largest 10 shareholders include FMR LLC (4.41M shares), Redmile Group, LLC (991K shares), BlackRock Advisors LLC (971K shares), ADAGE CAPITAL PARTNERS GP LLC (800K shares), Visium Asset Management, LP (701K shares), FRANKLIN RESOURCES INC (499K shares), BlackRock Fund Advisors (479K shares), VANGUARD GROUP INC (449K shares), WALL STREET ASSOCIATES (371K shares), and Sarissa Capital Management LP (360K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.